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Abstract SDS^PAGE analyses of stable HLA-DR1 complexes
indicate that the binding of T cell epitopes can lead to multiple
conformational variants. Whereas short T epitopes (614-mer)
induce complexes with apparent MW ranging from 47 to 57 kDa,
longer peptides form generally high mobility complexes (44^45
kDa). The generation of HLA-DR1 conformational variants
appears dependent on core peptide residues fitting inside the
groove but can additionally be attributed to the presence of N-
and C-terminal flanking residues (PFRs) acting as a comple-
mentary mechanism. These PFRs can jointly affect major
histocompatibility complex class II conformation and stability,
supporting the existence of alternative contacts at a distance
from the classical binding site. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The function of the major histocompatibility complex
(MHC) class II glycoproteins is to present antigenic peptides
derived from exogenous antigens to CD4 helper T cells [1].
Structural characterization of MHC class II heterodimers has
identi¢ed a peptide binding groove composed of the N-termi-
nal K1 and L1 domains whilst the membrane proximal K2 and
L2 domains share an immunoglobulin-like conformation [2^
5]. The length of naturally presented peptides comprises 12^25
residues [6,7] but MHC class II molecules recognize only a
nine residue binding frame within the sequence of the peptide
ligand. Pockets spaced within the overall MHC binding site
accommodate side chains of the core peptide sequence and
contribute to the peptide binding motif. In the structure of
HLA-DR alleles, pockets are at P1, P4, P6 and P9 with a
smaller one at P7. Additional residues at the amino- or car-
boxy-terminus extending out of the binding cleft have no ef-
fect on binding a⁄nity but play a role in stabilizing (KL)
heterodimers [8^10].
Several studies have reported the existence of conformation-
al variation in MHC class II folding states. Intermediate ‘£op-
py’ species, with reduced mobility in SDS^PAGE, were ¢rst
described in response to low pH or elevated temperatures
[11,12]. In addition, peptide binding to MHC class II mole-
cules drives a slow conversion between two distinct states, one
with unstable and looser conformation, the other with a long
half-life and SDS stability [13^15].
Moreover, several works have demonstrated the additional
role of peptides in the formation of mature MHC class II
molecules with di¡erent conformations. Indeed, based on
monoclonal antibody [16^18] and superantigen reactivities
[19^21], but also on SDS^PAGE mobility [17,22], subsets of
MHC class II expressed by presenting cells can be de¢ned by
the presence of particular peptides. However, molecular mech-
anisms that could be responsible for these changes remain
unresolved. Here, we study the in£uence of peptide ligand
residues on HLA-DR1 conformational changes.
2. Materials and methods
2.1. Peptide synthesis
Peptides were elaborated on a Rink Amide resin (France Biochem,
Meudon, France) using the Fmoc/tert-butyl strategy [36] and HBTU/
HOBT activation in an Applied Biosystems A431 peptide synthesizer
(Foster City, CA, USA). All the peptides were puri¢ed by RP-HPLC
using a water^acetonitrile linear gradient containing 0.05% tri£uoro-
acetic acid and characterized by amino acid analysis and TOF-PDMS
(Bio-Ion 20 Plasma Desorption Mass Spectrometer, Uppsala, Swe-
den). Sequences of all peptides are indicated in Table 1. The synthetic
undecapeptide XYX9 library was a kind gift of Dr. Burkhard Fleck-
enstein [23].
2.2. Expression of recombinant HLA-DRB1*0101 proteins
Recombinant baculovirus for both K and L chains was a generous
gift from L.J. Stern and D.C. Wiley (Harvard University, Cambridge,
MA, USA) [37]. The soluble human class II DR1 proteins were gen-
erated in Sf9 cells (Spodoptera frugiperda) or in BTI-Tn-5B1-4 cells
(Trichoplusia ni) purchased from Invitrogen (The Netherlands). Cells
were grown in X-press medium (Biowhittaker, Malkersville, MD,
USA). Four days post-infection, soluble DR1 proteins were puri¢ed
from medium and cell lysates on immunoa⁄nity columns with protein
A-Sepharose beads CL-4B (Sigma) coupled with the conformation-
sensitive monoclonal antibody L243 (ATCC). The elution step was
performed with glycine bu¡er pH 11.5, immediately neutralized with
glycine 2 M pH 3. After dialysis against phosphate-bu¡ered saline,
MHC heterodimers were concentrated up to 1 mg/ml on a Centricon
30 (Amicon, Beverly, MA, USA) and peptide binding capacity was
con¢rmed by its ability to form SDS^PAGE stable complexes with
peptide HA307ÿ319.
2.3. SDS^PAGE analysis
Acrylamide gel analyses were performed using SDS^PAGE with the
following modi¢cations. Samples were applied to the gel without
mercaptoethanol and without being boiled. Sample bu¡er contained
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100 mM Tris, 0.4% SDS and 20% glycerol diluted at 1:4. Gels were
run at low voltage to prevent temperatures exceeding 40‡C. The sep-
aration gel used was 12.5% acrylamide/bisacrylamide (37.5/1). Acryl-
amide gels were stained with Coomassie brilliant blue R250 and were
scanned on a Bio-Rad densitometer (quantitative analysis was per-
formed using Molecular Analysis I software).
2.4. Binding assays
Biotinylated HA307ÿ319 was incubated at a ¢nal concentration of
0.1 WM with 10 nM of HLA-DR1 protein for 48 h at 37‡C in the
absence or presence of unlabeled peptide at ¢nal concentrations rang-
ing from 1 nM to 100 WM. Samples were then added to ELISA plates
coated with the monoclonal antibody L243. Bound biotinylated
HA307ÿ319 was analyzed by streptavidin coupled to peroxidase en-
zyme.
2.5. Size exclusion chromatography
Gel ¢ltration analyses were performed on a TSK3000PW0.75U30
column (TosoHaas, Montgomeryville, PA, USA). Separations were
performed in phosphate-bu¡ered saline at room temperature at a
£ow rate of 0.5 ml/min. Calibration was done with 50 Wg of several
standard modi¢ed proteins (Bio-Rad): Q-globulin (158 kDa), bovine
serum albumin (82 kDa), ovalbumin (44 kDa), carbonic anhydrase
(34 kDa) and myoglobin (17 kDa).
2.6. Circular dichroism (CD)
Peptide/MHC complexes were prepared by incubating MHC class
II proteins at a concentration of 300 Wg/ml with 50 WM of each pep-
tide. After 96 h incubation at 37‡C, free peptide was removed by
dialysis with Spectra/por 25000 against 10 mM phosphate bu¡er.
CD measurements were performed using a spectropolarimeter (Jo-
bin-Yvon CD-6) equipped with a thermo-electric cell holder. Spectra
were recorded in the far UV between 190 and 260 nm, using a 0.1 cm
path length cell using a step size of 0.05 cm and a time constant of 5 s.
Temperature was increased from 25 to 90‡C with a step mode (5^
10‡C) with each temperature change followed by a 60 s equilibration
time.
3. Results
3.1. Binding of di¡erent T cell epitopes induces multiple
conformations of MHC class II HLA-DR1 complexes
Several peptide ligands were incubated with soluble DR1
molecules to generate stable (KL) heterodimers before SDS^
PAGE analysis under non-reducing, non-boiling conditions
(Fig. 1). Short peptides (6 14-mer, Fig. 1A) induce stable
complexes migrating with distinct mobility (MW 46^57
kDa). Interestingly, an undecapeptide library XYX9 leads to
the observation of a wide electrophoretic band compared to
unique peptides (Fig. 1B), suggesting the existence of a family
of peptide/DR1 isoforms. The presence of a tyrosine at the
second position of the library was designed to ensure an op-
timal contact with the dominant P1 pocket of DR1 and to
prevent peptide shifting on the binding cleft [23]. These results
indicate that distinct MHC class II conformations can be
induced by short peptides, depending on the residues ¢tting
inside the binding groove. Interestingly, we did not observe
any correlation between the apparent MW of DR1 complexed
with short ligands and non-related binding parameters such as
relative a⁄nity and stability (see Table 2), indicating the ex-
istence of an unknown mechanism for the formation of MHC
class II isoforms.
Longer peptides (s 14-mer) with residues extended outside
the groove generally lead to complexes with higher mobility.
Indeed, elongation of minimal T cell epitopes, such as
TT830ÿ850 and HA301ÿ331, induce the formation of 44^45
kDa complexes (Fig. 1C, lanes 1 and 3). Curiously,
SM24ÿ43, a 20-mer T cell epitope from Schistosoma mansoni
[24], stabilizes two distinct conformational forms with respec-
tively 45 and 78 kDa (Fig. 1C, lane 4). The nature of
SM24ÿ43, containing a single putative anchor motif (see Ta-
ble 1) and used in large excess to form the complexes, excludes
the possible binding of two (KL) heterodimers with a single
peptide ligand.
Size exclusion chromatography was performed on these
peptide/DR1 complexes to correlate the electrophoretic mo-
bility with the hydrodynamic radius (Fig. 2). Complexes with
44^57 kDa apparent MW in SDS^PAGE have close elution
pro¢les that were not considered signi¢cantly di¡erent. In
this, we were not able to correlate the measurement of appar-
ent molecular weight observed in SDS^PAGE and in gel ¢l-
tration probably due to the di¡erent conditions used for the
protein separation, notably the SDS. In turn, the SM24ÿ43/
DR1 complexes revealed a biphasic elution pro¢le. The ¢rst
part of this pro¢le is close to the retention time of a 82 kDa
marker protein. This hydrodynamic alteration is in accor-
dance with the formation of a 78 kDa isoform observed in
SDS^PAGE (Fig. 1C).
3.2. In£uence of peptide £anking regions (PFRs) on
HLA-DR1 conformation and stability
Extensions of minimal peptide ligands seem to have a pro-
Table 1
Abbreviations and sequences of peptide ligands
Peptide sequences are aligned according to their HLA-DR1 motif. Peptide binding cores were determined by the presence of a HLA-DR1 se-
quence motif obtained by experimental studies [38,39] or by prediction (*) according to the published HLA-DR1 anchor motif [23]. Peptide
binding cores covering nine residues (between P1 and P9) are represented in gray.
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found in£uence on DR1 conformation. To determine more
speci¢cally the importance of PFRs in determining HLA-
DR1 structure, N- and C-terminal elongations of di¡erent
minimal binding sequences were investigated.
Fig. 3A shows that binding of CLIP81ÿ103 generates SDS-
resistant DR1 complexes with lower apparent MW relative to
the complexes obtained with CLIP89ÿ103. This has been pre-
viously noticed but its relevance has been disputed considering
the di¡erence of mobility as an electrophoretic artefact in-
duced by the presence of the N-terminal part of CLIP81ÿ103
[25]. In contrast, when the N-terminal part of CLIP was
linked to the HA epitope (HACLIP, see Table 2), no di¡erence
in electrophoretic mobility was observed compared to HA/
DR1 complexes (Fig. 3B). In this, the CLIP81ÿ89 residues
dictate HLA-DR1 conformation but this e¡ect is not neces-
sarily transferable to another peptide ligand. These data sug-
gest a possible interaction of CLIP81ÿ89 residues with MHC
residues distant from the N-terminal binding groove. Critical
MHC residues may be engaged in this binding and cause the
whole molecule to undergo a structural transition. This hy-
pothesis was ¢rst suggested by Kropshofer et al. [26,27] who
identi¢ed N-terminal residues of CLIP (lysine 83, lysine 86,
proline 87) responsible for the reduction of MHC class II
stability. In contrast, we observed rather a conformational
change and maintenance of HLA-DR1 stability (see Table
2) in the presence of CLIP81ÿ89 suggesting the existence of
multiple distinct molecular mechanisms associated with the
binding of the CLIP peptide.
On the other hand, C-terminal elongation of the minimal
TT830ÿ843 peptide with leucine (TTL), leucyl-lysine (TTLK),
or leucyl-lysyl-lysine (TTLKK) increases the electrophoretic
mobility of the corresponding complexes, from 55 to 44
kDa (Fig. 3C). The more pronounced e¡ect was observed
with the addition of lysine 845 which increases the apparent
MW to 8 kDa. C-terminal elongation of TT is also accom-
panied by an increase in the thermostability of peptide/DR1
complexes (56‡C for TT compared to 63‡C for TTLKK, see
Table 2), a phenomenon independent of relative binding af-
¢nity. Together, these results indicate the role of C-terminal
residues extending outside the binding site in determining
jointly MHC class II conformation and stability.
3.3. CD analysis of stable peptide/HLA-DR1 complexes
Far-UV CD spectroscopy was previously used to compare
the secondary structure of empty and peptide-¢lled MHC
class II [28]. The spectra present a broad absorption band
from 210 to 230 nm, consistent with a protein containing a
substantial amount of L-sheet and a portion of K-helical struc-
ture.
Conformational variations between HA/DR1 and TTLKK/
Table 2
In£uence of speci¢c HLA-DR1 peptides on apparent MW, thermal
stability and relative a⁄nity
Peptide Apparent MWa Tbm (‡) Relative a⁄nity
c
HA 57 70 0.1
MYO 54 42 10
NEF 47 63 nt
TT 55 56 0.8
TTL 53 57 0.8
TTLK 45 62 0.85
TTLKK 44 63 0.9
SM24ÿ43 45/79 55 25
CLIP89ÿ103 56 62 1
CLIP81ÿ103 44 59.5 0.6
HACLIP 57 nt 0.1
nt: not tested.
aApparent molecular weights are representative of the electrophoret-
ic mobility of stable peptide/HLA-DR1 complexes in SDS^PAGE
under non-boiling, non-reducing conditions. Values are expressed in
kDa.
bMelting temperature (Tm) corresponds to the temperature at which
50% of stable complexes are dissociated. Each sample containing
stable peptide/HLA-DR1 complexes was heated for 10 min at tem-
peratures ranging from 40 to 85‡C before loading on non-reducing,
non-boiling SDS^PAGE. Densitometric analysis was performed to
calculate the ratio of stable (KL) heterodimers versus dissociated
chains and the values for the midpoint transition (Tm) were calcu-
lated.
cRelative a⁄nity (IC50) is measured in a heterologous competition
assay. Soluble HLA-DR1 molecules are incubated with di¡erent
concentrations of the peptide in the presence of biotinylated
HA307ÿ319 at 0.1 WM. After 48 h incubation at 37‡C individual
samples were analyzed by ELISA. Results are expressed in WM as a
mean of at least two independent experiments.
Fig. 1. Peptide binding-induced DR1 complexes with di¡erent mo-
bilities in SDS^PAGE. DR1 was incubated with a large excess of
peptide ligands. Stable MHC complexes were assessed in 12.5% ac-
rylamide SDS^PAGE analysis under non-reducing non-boiling con-
ditions. A: In£uence of short T helper epitopes on HLA-DR1 elec-
trophoretic mobility: empty HLA-DR1 (lane 1), TT/DR1 (lane 2),
HA/DR1 (lane 3), NEF/DR1 (lane 4), MYO/DR1 (lane 5). B: In-
£uence of a undecapeptide library XYX9 on HLA-DR1 mobility.
C: Longer T helper epitopes associated with HLA-DR1: TT830ÿ850
(lane 1), HA301ÿ331 (lane 2), HA (lane 3), SM24ÿ43 (lane 4) and
empty HLA-DR1 (lane 5).
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DR1 complexes were monitored by far-UV CD (Fig. 4). These
two stable complexes possess very distinct SDS^PAGE mobil-
ity and high thermostability (see Table 2). The contribution of
peptide ligands to the ellipticity was found to be negligible
and the absence of aggregate complexes was checked by gel
¢ltration (data not shown). At neutral pH, the spectra of both
complexes are very similar to each other with a broad mini-
mum centered at 216^218 nm characteristic of proteins with a
portion of K-helical structure and a substantial amount of L-
sheet. The analysis was then performed in the presence of
SDS, an optically neutral surfactant. We used the detergent
at a concentration of 0.1% at which both complexes (KL+pep-
tide) are resistant to dissociation and lack of the peptide at
25‡C (data not shown). The addition of 0.1% SDS in each
sample induces a change in secondary structure for both com-
plexes, but this change was less pronounced for DR1/TTLKK
complexes even at elevated temperatures (Fig. 4). In this, the
presence of SDS revealed structural di¡erences between stable
peptide/HLA-DR1 complexes and suggested the importance
of a hydrophobic site on these conformational changes.
4. Discussion
Several studies based on monoclonal antibody or superan-
tigen reactivities have demonstrated the role of peptide se-
quences in determining MHC class II structural changes on
antigen presenting cell surface [16,18,21]. Recently Chervon-
sky et al. [17] showed that structural transitions imposed by
peptides upon murine MHC class II molecules could a¡ect T
cell recognition. However, molecular mechanisms that could
account for this phenomenon remain unresolved. Our study
demonstrates the role of peptide ligands in determining con-
formational changes on MHC class II molecules. The alter-
native forms of HLA-DR1 seem to be di¡erent from the pre-
viously described MHC £oppy conformation. Floppy
isoforms were obtained after exposure of MHC class II mol-
ecules to acidic pH or elevated temperature [29] and were
associated with an unfolded intermediate state that could pro-
mote peptide loading in the endosome. Here, conformational
changes of DR1/peptide complexes are spontaneously driven
by the peptide, independent of parameters such as tempera-
ture, incubation time or pH. The results obtained with short T
epitopes (6 14-mer) including the undecapeptide library indi-
cate that the contact between peptide ligands and MHC class
II residues within the binding groove may be responsible for
changes observed in electrophoretic mobility of the DR1 com-
plexes. Peptide ligands are known to accommodate in the
binding groove of MHC class II with small rearrangement
of MHC residues. Indeed, conformational alterations between
two crystal structures of HLA-DR1 complexed with
HA307ÿ319 or A2103ÿ117 were observed in a £exible ‘kink’,
located in the K-helix of the L-chain, a region that may vary
according to the peptide side chain near the P7 pocket [5,30].
This subtle molecular mechanism could explain the di¡erence
in electrophoretic mobility of MHC class II complexes formed
with minimal peptide epitopes and may be related to the al-
tered antibody reactivities or T cell recognition observed in
other studies [16,17].
Observations made with longer peptides (s 14-mer) suggest
that PFRs extending outside the groove play an additional
role in determining MHC class II structure. The C-terminal
extension of TT peptides reduce the apparent molecular
Fig. 3. N- and C-terminal extension of peptide ligands in£uence the
HLA-DR1 electrophoretic mobility. 5 Wg of soluble DR1 was incu-
bated for 4 days at 37‡C in the presence of 100 WM of peptides.
The peptide/DR1 complexes were analyzed on SDS^PAGE under
non-reducing, non-boiling conditions. A: Relative migration of
HLA-DR1 complexes associated with CLIP89ÿ103 (lane 1) or
CLIP81ÿ103 (lane 2). B: Relative migration of HLA-DR1 com-
plexed with HACLIP (lane 1), HA (lane 2) and CLIP81ÿ103 (lane 3).
Empty HLA-DR1 is presented lane 4. C: Relative migration of
HLA-DR1 complexes formed with TT (lane 1) peptide, TTL (lane
2), TTLK (lane 3) and TTLKK (lane 4).
Fig. 2. Size exclusion chromatography of HLA-DR1/peptide com-
plexes. The elution pro¢le of di¡erent HLA-DR1/peptide complexes
were analyzed relative to di¡erent molecular markers as references.
Three complexes with di¡erent SDS^PAGE mobilities are presented:
HLA-DR1/HA, a 57 kDa isoform, HLA-DR1/NEF, a 47 kDa iso-
form, and HLA-DR1/SM leading to two di¡erent isoforms with re-
spectively 45 and 78 kDa.
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weight of complexes and concurrently increase thermostabil-
ity, results that strongly suggest the existence of some contact
outside the binding site. These potential contacts have been
previously proposed to explain the positive or negative in£u-
ence of N- and C-terminal extension of peptide ligands on
MHC class II stability [9,26]. Moreover, direct evidence using
photoa⁄nity labeling has suggested the existence of a contact
site beyond the peptide binding site to a nearby area in the K2
and L2 domains [31]. In this, one epitope could be presented
by di¡erent MHC class II isoforms depending on the nature
of the N- or C-terminal part of the ligand extending outside
the classical binding site. However, the in£uence of exopepti-
dases that participate in antigen processing and in the trim-
ming of peptides associated with class II molecules may nat-
urally limit the presence of PFRs and the interaction with
e¡ector binding sites distant from the classical groove.
We postulate that the conformational changes induced by
N- or C-terminal extension of minimal T cell epitopes may
preferentially a¡ect the structure of the K2 and L2 distal do-
mains as previously suggested by photoa⁄nity labeling experi-
ments [31]. This hypothesis is also in agreement with the CD
analysis of two distinct peptide/HLA-DR1 complexes. At
25‡C and in the presence of SDS, the conformation of both
species is di¡erent while the peptide ligand still remains tightly
bound to the K1-L1 peptide binding domain. Interactions be-
tween domains of the (KL) heterodimer are known to be
modulated by large pockets under the L-sheet from the pep-
tide binding domain. These interactions consist in hydropho-
bic patches [30] that could be responsible for MHC conforma-
tional variations observed in SDS^PAGE and CD analysis
due to SDS binding. The K2 and L2 domains were also pre-
viously implicated in a mechanism proposed for I-Ek confor-
mational changes occurring at mildly acidic pH [32]. In any
case, it is clear that the conformational variations observed
with soluble DR1 molecule lacking transmembrane and intra-
cellular parts are much more important compared to complete
(KL) heterodimers [33]. In this, the absence of structural con-
straints at the proximal part of the protein may increase the
amplitude of molecular changes observed in our studies.
The existence of multiple con¢gurations of MHC class II
molecules may have an impact on T cell reactivity as previ-
ously demonstrated [17]. Peptide ligands presented by MHC
class II molecules represent a small part of the contact area
with the T cell receptor and if we consider the ability of a
single immunogenic peptide to be presented in di¡erent topo-
logical con¢gurations induced by adjustment of MHC resi-
dues, an expanded spectrum of T cell reactivities could be
elicited. However, MHC class II conformational changes in-
duced by peptide ligand may have other implications. Indeed,
during intracellular tra⁄cking, MHC class II molecules inter-
act with chaperone molecules (such as HLA-DM), a mecha-
nism that has previously been demonstrated to be MHC class
II conformation-dependent [34]. Moreover, the conformation
of MHC class II has recently been demonstrated to in£uence
the selectivity of transport to the cell surface [35], a mecha-
nism that can now be imputable to the presence of di¡erent
peptide ligands on the MHC class II binding site. These hy-
potheses are now the subject of current investigations.
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